These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35192052)

  • 21. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Application of Next-Generation Sequencing-Based Panel to
    Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
    Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
    Scolyer RA; Atkinson V; Gyorki DE; Lambie D; O'Toole S; Saw RPM; Amanuel B; Angel CM; Button-Sloan AE; Carlino MS; Ch'ng S; Colebatch AJ; Daneshvar D; Pires da Silva I; Dawson T; Ferguson PM; Foster-Smith E; Fox SB; Gill AJ; Gupta R; Henderson MA; Hong AM; Howle JR; Jackett LA; James C; Lee CS; Lochhead A; Loh D; McArthur GA; McLean CA; Menzies AM; Nieweg OE; O'Brien BH; Pennington TE; Potter AJ; Prakash S; Rawson RV; Read RL; Rtshiladze MA; Shannon KF; Smithers BM; Spillane AJ; Stretch JR; Thompson JF; Tucker P; Varey AHR; Vilain RE; Wood BA; Long GV
    Pathology; 2022 Feb; 54(1):6-19. PubMed ID: 34937664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
    Kennedy OJ; Kicinski M; Valpione S; Gandini S; Suciu S; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Robert C; Eggermont AMM; Lorigan P; Mandala M
    Eur J Cancer; 2023 Aug; 189():112900. PubMed ID: 37277264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
    Polivka J; Gouda MA; Sharif M; Pesta M; Huang H; Treskova I; Woznica V; Windrichova J; Houfkova K; Kucera R; Fikrle T; Ricar J; Pivovarcikova K; Topolcan O; Janku F
    Cancer Med; 2024 Oct; 13(19):e70313. PubMed ID: 39387479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage Ⅱ-Ⅲ melanoma].
    Ren ZG; Xu Y; Hua ZZ; Mo ZY; Wang LW; Shi GB; Liu WL; Sun W; Zheng BQ; Wang CM; Jin YJ; Chen Y
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):973-980. PubMed ID: 37968084
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
    Dalle S; Varey E; Nguyen JM; Dupuy A; Montaudie H; Lesage C; Mortier L; Leccia MT; Skowron F; Celerier P; Meyer N; Dutriaux C; Dalac-Rat S; Khammari A; Lebbe C; Dréno B
    Eur J Dermatol; 2020 Aug; 30(4):389-396. PubMed ID: 32815816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
    BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
    Lodde GC; Hassel J; Wulfken LM; Meier F; Mohr P; Kähler K; Hauschild A; Schilling B; Loquai C; Berking C; Hüning S; Eckardt J; Gutzmer R; Reinhardt L; Glutsch V; Nikfarjam U; Erdmann M; Beckmann CL; Stang A; Kowall B; Galetzka W; Roesch A; Ugurel S; Zimmer L; Schadendorf D; Forschner A; Livingstone E
    Eur J Cancer; 2023 Sep; 191():112957. PubMed ID: 37487400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.
    Christofyllakis K; Pföhler C; Bewarder M; Müller CSL; Thurner L; Rixecker T; Vogt T; Stilgenbauer S; Yordanova K; Kaddu-Mulindwa D
    Front Oncol; 2020; 10():637161. PubMed ID: 33680957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
    Tawbi HA; Robert C; Brase JC; Gusenleitner D; Gasal E; Garrett J; Savchenko A; Görgün G; Flaherty KT; Ribas A; Dummer R; Schadendorf D; Long GV; Nathan PD; Ascierto PA
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma.
    Geidel G; Parnian N; Meß C; Schlepper N; Rünger A; Heidrich I; Hansen I; Smit DJ; Menz A; Pantel K; Schneider SW; Kött J; Gebhardt C
    J Eur Acad Dermatol Venereol; 2024 Oct; 38(10):2017-2023. PubMed ID: 38877773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
    Tas F; Erturk K
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [he role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma].
    Spagnolo F
    Recenti Prog Med; 2020 Dec; 111(12):39e-47e. PubMed ID: 33362181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
    Panka DJ; Buchbinder E; Giobbie-Hurder A; Schalck AP; Montaser-Kouhsari L; Sepehr A; Lawrence DP; McDermott DF; Cohen R; Carlson A; Wargo JA; Merritt R; Seery VJ; Hodi FS; Gunturi A; Fredrick D; Atkins MB; Iafrate AJ; Flaherty KT; Mier JW; Sullivan RJ
    Mol Cancer Ther; 2014 Dec; 13(12):3210-8. PubMed ID: 25319388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma.
    Ma VT; Daignault-Newton S; Waninger JJ; Journey S; Chopra Z; Tezel A; Redman BG; Fecher LA; Green MD; Alva AS; Lao CD
    Pigment Cell Melanoma Res; 2021 May; 34(3):629-640. PubMed ID: 33128316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.